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CD4+ T cells orchestrate the recruitment and 
subsequent activation of innate and adaptive 
immune cells in the tissue through the produc-
tion of cytokines and critically contribute to 
the generation of a robust immune response to 
invading pathogens (Reinhardt et al., 2006). 
A prerequisite for CD4+ T cell participation in 
host defense is their recruitment into periph-
eral nonlymphoid tissue both in response to 
pathogens and at homeostasis so that antigen-
experienced T cells are positioned where patho-
gen reencounter is most likely to occur. The 
mechanisms that govern this strategic distribu-
tion of T cells into tissues are not fully defined.
Organs with large epithelial surfaces such 
as the gut and the skin are in constant contact 
with the environment and are exposed to po-
tential pathogens on a regular basis and there-
fore need an efficient immune response strategy 
to prevent infections at these sites. The unique 
structure and function of each organ determine 
its exposures and vulnerabilities to specific 
pathogens and make reexposure to a particular 
pathogen more likely in the same organ. For 
example, by virtue of its ecology, the gut is 
susceptible to infection with Salmonella and 
Shigella, organisms which are not pathogens in 
the skin. To streamline T cell memory immune 
responses based on the predictability of pathogen 
reexposure, the gut and the skin have evolved 
tissue-selective T cell imprinting, a process 
whereby DCs derived from the gut instruct 
T cells to home preferentially into the gut, 
whereas DCs derived from the skin instruct 
T cells to preferentially home into the skin. Gut 
DCs imprint the expression of 47 and CCR9 
on T cells, and in doing so enable their entry 
into the small intestine in response to intestinal 
MAdCAM-1 and CCL25, respectively (Stagg 
et al., 2002; Johansson-Lindbom et al., 2003; 
Mora et al., 2003). Similarly, skin-derived DCs 
imprint T cell expression of P- and E-selectin 
ligands and CCR10, allowing T cell skin homing 
via cutaneous P- and E-selectins and CCL27, 
respectively (Campbell and Butcher, 2002; Dudda 
et al., 2004; Sigmundsdottir et al., 2007). This 
may explain why peripheral blood memory 
T cells that proliferate in response to rotavirus, 
a gut pathogen, are 47+ (Rott et al., 1997), 
whereas peripheral blood T cells specific for 
herpes simplex virus 2, a skin tropic virus, ex-
press high levels of CLA (Koelle et al., 2002). 
The unique structure and function of each organ 
also offer a distinct set of tissue-specific autoan-
tigens, such that the autoantigens generated in 
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T cell trafficking into the lung is critical for lung immunity, but the mechanisms that 
mediate T cell lung homing are not well understood. Here, we show that lung dendritic cells 
(DCs) imprint T cell lung homing, as lung DC–activated T cells traffic more efficiently into 
the lung in response to inhaled antigen and at homeostasis compared with T cells activated 
by DCs from other tissues. Consequently, lung DC–imprinted T cells protect against influ-
enza more effectively than do gut and skin DC–imprinted T cells. Lung DCs imprint the 
expression of CCR4 on T cells, and CCR4 contributes to T cell lung imprinting. Lung  
DC–activated, CCR4-deficient T cells fail to traffic into the lung as efficiently and to 
protect against influenza as effectively as lung DC–activated, CCR4-sufficient T cells. Thus, 
lung DCs imprint T cell lung homing and promote lung immunity in part through CCR4.
© 2013 Mikhak et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
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[left, BAL: 5-, 4-, 2.6-, 5-, 22-, and 2.6-fold, respectively; right, 
lung: 3.7-, 3.4-, 2.3-, 3.5-, 5.3-, and 2-fold, respectively]). 
Because Flt3L does not expand alveolar macrophages (von 
Wulffen et al., 2007; Hao et al., 2008), we show that the lung 
DC preparation used in these experiments contained <1% 
alveolar macrophages defined as autofluorescent CD11c+ cells 
(Fig. 1 c; Lambrecht and Hammad, 2012). There was no dif-
ference in the number of Thy1.1+ OTII cells in the spleen or 
Peyer’s patches (PPs; Fig. 1 d). Consistent with their enhanced 
lung homing, lung DC–activated T cells induced more in-
flammation in the lungs of recipient mice compared with 
skin DC–activated T cells (Fig. 1 e).
To ensure that Flt3L did not cause the lung-homing ad-
vantage of lung DC–activated T cells, we repeated these ex-
periments using DCs isolated from mice that were not treated 
with Flt3L. Because these untreated mice did not have an ex-
panded population of DCs, tissues were pooled from up to 
20 mice per experiment to obtain adequate numbers of DCs. 
Single cell preparations of unexpanded tissues were rested 
overnight. The next day, nonadherent cells were collected, 
and CD11c+ cells were isolated with purity >97% (not de-
picted). After the overnight incubation and exclusion of ad-
herent cells, the percentage of alveolar macrophages in the 
lung DC preparation of unexpanded mice was 17 ± 4% (not 
depicted). DCs were used to activate CD4+ T cells in vitro, 
yielding similar levels of T cell differentiation and activation 
(not depicted), followed by adoptive transfer experiments as 
described above. Despite the presence of some alveolar mac-
rophages in the lung DC preparations from unexpanded mice, 
lung DC–activated T cells trafficked significantly more effi-
ciently into the BAL and lung compared with spleen and 
SLN DC–activated T cells (Fig. 1 f, left, BAL: 9- and 10-fold, 
respectively; right, lung: 2.5- and 6.6-fold, respectively).
We saw similar results when we studied antigen-specific 
CD8+ T cells. DCs from Flt3L-expaned mice were used to 
activate CD8+ T cells isolated from Thy1.2+ OTI mice, which 
are transgenic for the TCR recognizing OVA peptide 257–
264 (pOVA257–264). Adoptive transfer experiments were 
performed as described above in Thy1.1+ mice. Lung DC–
activated OTI cells trafficked significantly more efficiently into 
the BAL and lung compared with spleen, SLN, and MLN 
DC–activated OTI cells (Fig. 1 g, left, BAL: 8.6-, 4.4-, and 
5.5-fold, respectively; right, lung: 23-, 4-, and 4.4-fold, respec-
tively). These results demonstrate that lung DCs endow T cells 
with a lung-homing advantage as lung DC–activated T cells 
were superior in lung homing in response to inhaled antigen.
No difference in proliferation and apoptosis
To assess proliferation in vivo, recipients of DC-activated 
T cells were given an i.p. dose of BrdU immediately before 
the third aerosolized OVA challenge, and TLNs were harvested 
2 h later (Mikhak et al., 2009). There was no statistically sig-
nificant difference in the total number of cells in the TLN of 
recipient mice (not depicted). Furthermore, we observed no 
difference in the percentage of CD4+Thy1.1+BrdU+ cells in the 
lymphocyte gate in the TLN in recipients of lung DC– versus 
the intestine would be different from those generated in the 
skin. Therefore, tissue-selective T cell imprinting might have 
also evolved to enable tissue-specific regulatory T cells to home 
efficiently to the location of their autoantigens.
Tissue-selective T cell imprinting was described a decade 
ago for the gut and the skin and to date has not been shown 
for any other organ, raising the possibility that it might be a 
phenomenon restricted to these two organs. Like the gut and 
the skin, however, the lung is a large epithelial organ in con-
tinuous contact with the environment and potential patho-
gens. The lung also has its own unique structure and function, 
specific pathogen susceptibility (i.e., pneumococcus and in-
fluenza), and autoantigens and thus is poised to benefit from 
tissue-selective T cell imprinting. Understanding whether lung 
DCs imprint T cell lung homing is fundamental to under-
standing T cell immunity to inhaled antigens and pathogens. 
Whether lung DCs instruct T cells to home to the lung has 
implications for vaccine development and potentially opens 
novel therapeutic approaches for a variety of inflammatory 
T cell–mediated lung diseases. Here, we sought to determine 
whether lung DCs imprint T cell lung homing and, if so, the 
impact of lung imprinting on lung immunity.
RESULTS
Lung DC–activated T cells home efficiently  
into the lung in response to inhaled antigen
To determine whether lung DCs imprint T cell lung homing, 
we compared the trafficking of antigen-specific CD4+ T cells 
activated by lung DCs versus those activated by DCs isolated 
from other sites into the lung in response to inhaled antigen. 
Naive C57BL/6 mice were injected with fms-like tyrosine 
kinase 3 ligand (Flt3L)-secreting melanoma cells to expand 
DC numbers (Mora et al., 2003). On days 12–14, DCs were 
isolated from the lung, thoracic LNs (TLNs), spleen, skin-
draining LNs (SLNs), mesenteric LNs (MLNs), ear skin, and 
lamina propria (LP) from the same pool of donor mice, with 
DC purity >95% (not depicted). DCs were used to activate 
CD4+ T cells isolated from Thy1.1+ OTII mice, which are 
transgenic for the TCR recognizing OVA peptide 323–339 
(pOVA323–339). DC–T cell cultures were established using 
pOVA323–339 without any exogenous cytokines. The use of 
OVA peptide eliminated the differences in the ability of DCs 
to take up and/or process antigen as a variable. By not using 
exogenous cytokines, we did not skew DC–T cell interactions 
toward any differentiation pathway. On day 6, DC-activated 
Thy1.1+ OTII cells demonstrated equivalent activation and 
differentiation (not depicted) before their adoptive transfer 
into separate naive Thy1.2+ recipient mice. Recipient mice 
were given three daily aerosolized OVA challenges and bron-
choalveolar lavage fluid (BAL), and lungs were harvested 24 h 
after the last challenge. The number of adoptively transferred 
CD4+Thy1.1+ cells in each site was compared between re-
cipients of DC-activated T cells.
Lung DC–activated T cells trafficked significantly more 
efficiently into the BAL and lung compared with TLN, spleen, 
SLN, MLN, skin, and LP DC–activated T cells (Fig. 1, a and b 
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The homing advantage of lung DC–activated T cells  
in response to antigen is specific to the lung
DC-activated T cells were adoptively transferred into separate 
naive recipient mice followed by oral, i.p., or epicutaneous 
OVA challenges. Tissues were harvested 24 h later. MLN 
DC–activated T cells trafficked 11.6- and 2.2-fold more effi-
ciently into LP and PPs compared with lung DC–activated 
T cells in response to oral OVA challenge (Fig. 2, a and b). 
This indicates that the impaired trafficking of MLN DC– 
activated T cells into the lung and the BAL in response to 
other DC-activated T cells (not depicted). To study apop-
tosis in vivo, we used 7-aminoactinomycin D (7-AAD) on 
lung samples obtained 24 h after the third OVA challenge. 
There was no difference in the percentage of CD4+Thy1.1+ 
7-AAD+ cells in the lymphocyte gate in the lung in recipi-
ents of lung DC– versus other DC-activated T cells (not 
depicted). These findings demonstrate that the enhanced ac-
cumulation of lung DC–activated T cells in the lung after 
antigen challenge is not caused by their increased prolifera-
tion or decreased apoptosis.
Figure 1. Lung DC–activated T cells home efficiently into the lung in response to inhaled antigen. DCs isolated from Flt3L-expanded C57BL/6 mice 
were used to activate Thy1.1+ OTII cells in vitro. DC-activated OTII cells were adoptively transferred into separate Thy1.2+ C57BL/6 recipient mice, followed by 
three inhaled OVA challenges. (a) BAL from recipients of DC-activated OTII cells were analyzed for Thy1.1+ (y axis) versus Thy1.2+ (x axis) expression in the 
CD4+ gate. (b) Thy1.1+ OTII cells in the BAL and lung from recipients of DC-activated T cells were enumerated 24 h after the last OVA challenge. n = 8–38 mice 
per group total from 2–10 independent experiments for a and b. P-values are calculated between recipients of lung DC– versus other DC-activated T cells. 
(c) Flow cytometry of lung DCs isolated from Flt3L-expanded mice gating on live CD11c+ cells, demonstrating the expression of CD11c (y axis) versus auto-
fluorescence (AF) in the FITC open channel (x axis). Data are representative of three independent experiments. (d) Thy1.1+ OTII cells in the spleen and PPs from 
recipients of DC-activated T cells were enumerated. n = 2–3 independent experiments. (e) Lung tissue from recipients of lung DC– versus skin DC–activated 
OTII cells were stained with H&E and scored by histology. n = 9–10 mice per group total from three independent experiments. Bars, 150 µm. (f) DCs isolated 
from unexpanded C57BL/6 mice were used to activate Thy1.1+ OTII cells in vitro, which were then adoptively transferred into separate Thy1.2+ C57BL/6 recipi-
ent mice, followed by three inhaled OVA challenges. Thy1.1+ OTII cells in the BAL and lung from recipients of DC-activated OTII cells were enumerated.  
n = 9–23 mice per group total from three to six independent experiments. (g) DCs isolated from Flt3L-expanded C57BL/6 mice were used to activate Thy1.2+ 
OTI cells in vitro. DC-activated OTI cells were adoptively transferred into separate Thy1.1+ C57BL/6 recipient mice, followed by three inhaled OVA challenges. 
Thy1.2+ OTI cells in the BAL and lung from recipients of DC-activated OTI cells were enumerated. n = 6–15 mice per group total from two to four independent 
experiments. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ****, P < 0.00005. Data are presented as mean (±SEM).
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the lung to the TLN upon exposure to inhaled antigen. We 
isolated DCs from the lung and TLN of Flt3L-expanded mice 
either 30 min or 24 h after an intranasal dose of OVA with 
or without an intranasal dose of CCR7 blocking antibody, 
which has been shown to diminish lung DC migration to the 
TLN (not depicted; Fainaru et al., 2005). CCR4 blocking 
antibody was used as a negative control. DC-activated T cells 
were adoptively transferred into separate naive recipient mice 
followed by three aerosolized OVA challenges. Lung DC– 
activated T cells trafficked 2.7-fold more efficiently into the 
lung compared with TLN DC–activated T cells when DCs 
were isolated 30 min after intranasal OVA before there was 
enough time for lung DC migration to the TLN. However, 
when DCs were isolated 24 h after intranasal OVA, which 
provided sufficient time for lung DC migration to the TLN 
(Vermaelen et al., 2001), there was no difference in the traf-
ficking of lung DC– and TLN DC–activated T cells into the 
lung. In contrast, when DC migration from the lung to the 
TLN was inhibited by the concurrent treatment of the mice 
with a CCR7 blocking antibody, TLN DC–activated T cells 
had a 2.3-fold trafficking defect into the lung (Fig. 3). This 
was not seen when mice were concurrently treated with a 
CCR4 blocking antibody (Fig. 3). The intranasal CCR7 and 
CCR4 blocking antibodies did not adversely affect lung DCs 
as lung DCs remained fully capable of activating T cells and 
imprinting lung homing. These data collectively suggest that 
the lung DC subset that imprints T cell lung homing is a mi-
gratory subset that travels from the lung to the TLN upon ex-
posure to inhaled antigen.
inhaled antigen was not caused by an overall in vivo functional 
deficit because these cells were capable of more efficiently 
trafficking into the gut compared with lung DC–activated 
T cells after oral antigen challenge. There was no difference in 
the trafficking of lung and MLN DC–activated T cells into 
the lung and spleen in response to oral OVA challenge (Fig. 2 a) 
or into PPs, lung, and spleen in response to i.p. OVA chal-
lenge (Fig. 2 c). To increase T cell trafficking into the ear skin 
to detectable levels, we used tape stripping before each epicu-
taneous OVA challenge and repeated the procedure once 
daily for 3 d. SLN DC–activated T cells trafficked 2.5-fold 
more efficiently into the ear skin compared with lung DC–
activated T cells in response to three daily tape strippings and 
epicutaneous OVA challenges (Fig. 2 d). There was no differ-
ence in the trafficking of lung and SLN DC–activated T cells 
into the lung and spleen in response to epicutaneous OVA 
challenges (Fig. 2 d). These observations indicate that lung 
DC–activated T cells do not have a trafficking advantage into 
all tissues in response to antigen, but instead have a specific 
homing advantage for the lung. Furthermore, consistent with 
the published literature showing that T cell imprinting is a 
flexible process (Mora et al., 2005; Liu et al., 2006; Oyoshi et al., 
2011), lung DC–activated T cells appear to lose their lung-
homing advantage upon reactivation and reprogramming in 
gut-draining LNs or SLNs.
Lung-imprinting DCs are migratory DCs
We next examined whether the lung DC subset that imprints 
T cell lung homing is a migratory DC subset that travels from 
Figure 2. The homing advantage of lung DC–activated T cells in response to antigen is specific to the lung. DCs isolated from Flt3L-expanded 
C57BL/6 mice were used to activate OTII cells in vitro. DC-activated T cells were adoptively transferred into separate recipient mice, followed by oral, i.p., 
or epicutaneous OVA challenges. DC-activated Thy1.1+ OTII cells were transferred into Thy1.2+ C57BL/6 recipients in a–c. DC-activated Thy1.2+ OTII cells 
were transferred into Thy1.1+ C57BL/6 recipients in d. (a) Thy1.1+ OTII cells in LP, PPs, lung, and spleen from recipients of lung DC– versus MLN DC–activated  
T cells were enumerated 24 h after one oral OVA challenge. (b) PPs from recipients of lung DC– versus MLN DC–activated T cells after one oral OVA chal-
lenge were analyzed for the expression of CD4+ (y axis) and Thy1.1+ (x axis, right) by flow cytometry. (c) Thy1.1+ OTII cells in PPs, lung, and spleen from 
recipients of lung DC– versus MLN DC–activated T cells were enumerated 24 h after one i.p. OVA challenge. (d) Thy1.2+ OTII cells in the ear skin, lung, and 
spleen from recipients of lung DC– versus SLN DC–activated T cells were enumerated 24 h after three daily tape strippings and epicutaneous OVA chal-
lenges. n = 12 mice per group total from three independent experiments in a and b for PPs, lung, and spleen. n = 6 mice per group total from two inde-
pendent experiments in a for LP and in c and d. *, P < 0.05. Data are presented as mean (±SEM).
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lung DC–activated T cells homed better into SLNs (HI = 1.4 ± 
0.14; Fig. 4, b [left] and c [top]). After cotransfer of lung and 
SLN DC–activated T cells, lung DC–activated T cells showed 
a modest lung-homing advantage over SLN DC–activated 
T cells (HI = 1.5 ± 0.06). There was no difference in spleen 
homing (HI = 1.0 ± 0.05). Lung DC–activated T cells homed 
more efficiently into PPs (HI = 1.4 ± 0.08), whereas lung and 
SLN DC–activated T cells showed similar homing into SLNs 
(HI = 0.9 ± 0.07; Fig. 4, b [right] and c [bottom]). Cumula-
tively, these results suggest that although lung DC–activated 
T cells have a lung-homing advantage, they maintain their 
ability to distribute into the gut and the skin at homeostasis.
Expression of trafficking molecules  
by lung DC–activated T cells
We determined that lung homing of lung DC–activated 
T cells was pertussis toxin (PTX) sensitive as PTX-treated lung 
DC–activated T cells had a significant trafficking defect into 
the BAL and lung after aerosolized OVA challenges (Fig. 5 a). 
To explain the trafficking patterns of lung DC–activated 
T cells, we next compared the expression of trafficking mole-
cules on the surface of lung DC– versus MLN and SLN DC–
activated T cells using flow cytometry on day 5 of culture, 
a day before their adoptive transfer. 42% (±5) of lung DC– 
activated T cells expressed CCR4, whereas only 21% (±3) of 
MLN DC–activated T cells were CCR4+. The expression of 
CCR4 on SLN DC–activated T cells was intermediate (32 ± 
5%) between lung and MLN DC–activated T cells (Fig. 5, b 
and c). 56% (±5) of MLN DC–activated T cells expressed 
47, whereas only 29% (±4) of SLN DC–activated T cells 
were 47+. The expression of 47 on lung DC–activated 
T cells was intermediate (40 ± 6%) between MLN and SLN 
DC–activated T cells (Fig. 5, c and d). CCR9 expression on 
lung and SLN DC–activated T cells was lower than that of 
MLN DC–activated T cells (Fig. 5, c and d, four- and eight-
fold lower, respectively). 32% (±2) of SLN DC–activated T cells 
and 31% (±1) of lung DC–activated T cells expressed E-selectin 
ligand, whereas only 19% (±2) of MLN DC–activated T cells 
were E-selectin ligand+ (Fig. 5, c and d). All other trafficking 
molecules tested were expressed at similar levels by lung, MLN, 
and SLN DC–activated T cells (Fig. 5 e).
Consistent with the published literature (Kallinich et al., 
2005; Thomas et al., 2007; Purwar et al., 2011), we noted 
CCR4 expression on 24% (±4) of CD4+ T cells in the naive 
lung, whereas expression levels were low for 47, CCR9, 
and E-selectin ligand (Fig. 5 f). Because CCR4 was the only 
trafficking molecule that was differentially expressed on lung 
DC–activated T cells and was also expressed on a consider-
able percentage of lung-resident CD4+ T cells, we set out to 
determine the role of CCR4 in the lung-homing advantage 
of lung DC–activated T cells.
CCR4 contributes to the lung-homing advantage  
of lung DC–activated T cells
We first determined whether the ligands for CCR4 were ex-
pressed in the lung to direct the trafficking of CCR4+ T cells. 
Lung DC–activated T cells home more efficiently  
into the lung at homeostasis
We next determined whether lung DC–activated T cells ex-
hibit enhanced lung homing at baseline in the absence of 
antigen. Lung, MLN, and SLN DC–activated T cells were 
adoptively transferred into separate naive mice without OVA 
challenges. 72 h after adoptive transfer, lung DC–activated 
T cells accumulated more efficiently in the BAL and lung of 
recipient mice compared with MLN and SLN DC–activated 
T cells (Fig. 4 a, left, BAL: 4.8- and 3-fold, respectively; right, 
lung, 2.4-fold).
To verify the lung-homing advantage of lung DC–activated 
T cells at homeostasis, we used competitive adoptive transfer 
experiments in the absence of antigen and assessed T cell lung 
homing at a shorter time point, 4 h after adoptive transfer. 
Lung DC–activated T cells were labeled with CFSE, whereas 
MLN and SLN DC–activated T cells were separately labeled 
with orange-fluorescent tetramethylrhodamine (CMTMR). 
CFSE-labeled, lung DC–activated T cells were mixed with 
CMTMR-labeled, MLN or SLN DC–activated T cells at 1:1 
ratio and adoptively transferred via the tail vein into naive re-
cipient mice. The ratio of input cells was determined using flow 
cytometry before adoptive transfer. 4 h after adoptive transfer, 
the percentage of CFSE+ and CMTMR+ cells was deter-
mined in the 7-AADCD4+ gate within the lymphocyte gate 
in the lung, spleen, PPs, and SLNs. Homing index (HI) was cal-
culated as [CFSE+/CMTMR+]tissue/[CFSE+/CMTMR+]input 
(Mora et al., 2003). Statistical significance was determined 
against spleen HI. Similar results were obtained when dyes 
were switched.
After cotransfer of lung and MLN DC–activated T cells, 
lung DC–activated T cells demonstrated a threefold lung 
homing advantage over MLN DC–activated T cells (HI = 3 ± 
0.4). There was no difference in spleen homing (HI = 1.1 ± 
0.03). Surprisingly, lung and MLN DC–activated T cells 
showed similar homing into PPs (HI = 1.1 ± 0.05), whereas 
Figure 3. Lung-imprinting DCs are migratory DCs. Lung and TLN DCs 
isolated from Flt3L-expanded C57BL/6 mice 30 min or 24 h after intranasal 
OVA with or without intranasal CCR7 or CCR4 blocking antibody were used 
to activate Thy1.1+ OTII cells in vitro. DC-activated T cells were adoptively 
transferred into separate Thy1.2+ recipient C57BL/6 mice, followed by three 
inhaled OVA challenges. Thy1.1+ OTII cells in the lung from recipients of 
lung DC– versus TLN DC–activated T cells were enumerated when DCs 
were isolated either 30 min or 24 h after intranasal OVA exposure.  
n = 7–20 mice per group total from two to five independent experiments. 
*, P < 0.05; ***, P < 0.0005. Data are presented as mean (±SEM).
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were obtained when dyes were switched. The HI into the 
lung after the cotransfer of lung and MLN DC–activated 
CCR4/ OTII cells was 1.6 (±0.06), a significant decrease 
from the HI into the lung after the cotransfer of lung and 
MLN DC–activated OTII cells (2.8 ± 0.3). The HI into the 
lung after the cotransfer of lung and SLN DC–activated 
CCR4/ OTII cells was 1.4 (±0.08), which was not signifi-
cantly different from the HI into the lung after the cotransfer 
of lung and SLN DC–activated OTII cells (1.6 ± 0.07; Fig. 6 c). 
Therefore, CCR4 deficiency diminished the lung-homing 
advantage of lung DC–activated T cells over MLN DC–
 activated T cells but not SLN DC–activated T cells.
We next investigated the functional role of CCR4 in 
T cell lung imprinting in response to inhaled antigen. Lung 
DC–activated, Thy1.2+ OTII and CCR4/ OTII T cells 
were generated in vitro and adoptively transferred into sepa-
rate naive Thy1.1+ recipient mice, followed by three daily 
aerosolized OVA challenges. Lung DC–activated OTII cells 
trafficked 4.6- and 1.9-fold more efficiently into the BAL and 
lung, respectively, compared with lung DC–activated CCR4/ 
OTII cells (Fig. 6 d). These data collectively demonstrate a 
functional role for CCR4 in lung DC imprinting of T cell 
lung homing.
Using quantitative PCR (QPCR), we found high expression 
levels of CCR4 ligands CCL17 and CCL22 in the lungs of 
naive mice (Fig. 6 a) compared with the ligands for CCR6 
(CCL20) and CXCR3 (CXCL9 and CXCL10), two other 
chemokine receptors expressed on a considerable percent-
age of lung-resident T cells. Using immunohistochemistry 
with a CCL17 monoclonal antibody, we found that CCL17 
was expressed in both airway epithelial cells as well as the 
luminal aspect of endothelial cells in the lungs of naive mice 
(Fig. 6 b, middle) and in the lungs of mice that received lung 
DC–activated T cells and three aerosolized OVA challenges 
(Fig. 6 b, right).
To delineate the functional role of CCR4 in T cell lung 
imprinting, we first used a competitive adoptive transfer model 
and asked whether CCR4 deficiency would diminish the 
lung-homing advantage of lung DC–activated T cells at homeo-
stasis. DCs were isolated from the lung, MLNs, and SLNs of 
Flt3L-expanded mice and used to activate OTII and CCR4/ 
OTII cells in vitro. Lung DC–activated OTII and CCR4/ 
OTII cells were labeled separately with CFSE, whereas SLN 
and MLN DC–activated OTII and CCR4/ OTII cells were 
labeled separately with CMTMR. Competitive adoptive trans-
fer experiments were performed as in Fig. 4. Similar results 
Figure 4. Lung DC–activated T cells home effi-
ciently into the lung at homeostasis. DCs isolated from 
Flt3L-expanded C57BL/6 mice were used to activate 
Thy1.1+ OTII cells in vitro. DC-activated T cells were adop-
tively transferred into separate recipient Thy1.2+ C57BL/6 
mice without OVA challenges. (a) Thy1.1+ OTII cells in the 
BAL and lung from recipients of DC-activated T cells were 
enumerated 72 h after adoptive transfer. n = 9 mice per group 
total from three independent experiments. (b and c) DCs were 
isolated from Flt3L-expanded mice. CFSE-labeled, lung 
DC–activated T cells and CMTMR-labeled, MLN DC– or 
SLN DC–activated T cells were mixed 1:1 and adoptively 
transferred into recipient mice without OVA challenges. 
(b) HI (y axis) for the lung, spleen, PPs, and SLNs (x axis) 
was determined 4 h after competitive adoptive transfer of 
lung DC– and MLN DC–activated T cells (left; n = 9 mice 
total from three independent experiments) and lung DC– 
and SLN DC–activated T cells (right; n = 9 mice total from 
three independent experiments). Gating on 7-AADCD4+ 
cells within the lymphocyte gate, HI was calculated as 
[CFSE+/CMTMR+]tissue/[CFSE+/CMTMR+]input. P-values are 
calculated between the HI for any tissue versus the HI for 
spleen. (c) CFSE+ lung DC–activated T cells (y axis) versus 
CMTMR+ MLN DC (x axis, top)– or SLN DC–activated  
T cells (x axis, bottom) were analyzed, demonstrating  
input cells and gated cells in the lung, spleen, PPs, and 
SLNs. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ****, P < 0.00005. 
Data are presented as mean (±SEM).
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Figure 5. Expression of trafficking molecules by lung DC–activated T cells. DCs isolated from Flt3L-expanded C57BL/6 mice were used to activate 
OTII cells in vitro in a–e. (a) Thy1.1+ DC-activated OTII cells were either treated or untreated with PTX and adoptively transferred into Thy1.2+ recipient 
mice, followed by three inhaled OVA challenges. Thy1.1+ OTII cells were enumerated in the BAL and lung from recipients of PTX-treated or untreated, lung 
DC–activated T cells. n = 6 mice per group total from two independent experiments. (b–e) DC-activated T cells were analyzed for expression of trafficking 
molecules on day 5. (b) Percentage (left) and mean fluorescence intensity (MFI; right) of CCR4+ lung DC–, MLN DC–, and SLN DC–activated T cells. n = 8 
independent experiments. (c) Flow cytometry of lung DC–, MLN DC–, and SLN DC–activated T cells demonstrating the expression of CD4 (x axis) versus 
CCR4 (top row), 47 (second row), CCR9 (third row), and E-selectin ligand (bottom row; y axis). (d) Percentage of 47+ (top), CCR9+ (middle), and  
E-selectin ligand+ (bottom) lung DC–, MLN DC–, and SLN DC–activated T cells. n = 6–10 separate cultures. (e) Percent expression of chemokine receptors 
(left) and integrins and selectin ligands (right) by lung DC–, MLN DC–, and SLN DC–activated T cells. n = 4–8 independent experiments. (f) Percent expres-
sion of chemokine receptors (left) and integrins and selectin ligands (right) by CD4+ T cells in the lymphocyte gate in lungs isolated from naive C57BL/6 
mice. n = 3–10 individual lungs. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ****, P < 0.00005. Data are presented as mean (±SEM).
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day 0. Recipients of lung DC–activated OTII cells lost weight 
until day 7 after infection, dropping 19 ± 2% of their original 
weight. Recipients of no cells and MLN DC–activated OTII 
cells continued to lose weight until day 11 after infection and 
showed a weight loss of 30 ± 1% and 28 ± 4%, respectively. 
Recipients of SLN DC–activated OTII cells and lung DC–
activated CCR4/ OTII cells had an intermediate response 
to infection as they lost weight until day 8 after infection and 
decreased their weight by 25 ± 2% and 23 ± 2%, respectively 
(Fig. 7 c). 90% of recipients of lung DC–activated OTII cells 
survived, whereas only 47%, 53%, 58%, and 70% of recipients 
of no cells, MLN DC–activated OTII cells, SLN DC–activated 
OTII cells, and lung DC–activated CCR4/ OTII cells sur-
vived infection with H1ova, respectively (Fig. 7 d). Finally, 
recipients of lung DC–activated OTII cells cleared their in-
fection by day 10, consistent with their more rapid weight 
gain at this time point, whereas recipients of no cells, MLN 
DC–activated OTII cells, SLN DC–activated OTII cells, and 
lung DC–activated CCR4/ OTII cells continued to har-
bor the influenza virus (Fig. 7 e). These data collectively dem-
onstrate that lung DCs promote lung immunity by imprinting 
T cell lung homing in part through CCR4.
DISCUSSION
We show that lung DCs imprint T cell lung homing as lung 
DC–activated T cells were superior in lung homing compared 
with other DC-activated T cells both in response to inhaled 
antigen and at homeostasis. Lung DCs imprinted lung-specific 
Lung DC–activated T cells protect against influenza
To determine the functional consequence of lung imprinting, 
we examined whether the enhanced accumulation of lung 
DC–activated T cells in the lung promoted lung immunity. 
We used a PR8-H1N1 strain of influenza that expresses 
pOVA323–339 in the hemagglutinin molecule (H1ova; Thomas 
et al., 2006) and studied the trafficking of CD4+ OTII T cells 
in the context of this infection when T cells were activated by 
lung DCs versus other DCs. To further delineate the role of 
CCR4 in lung imprinting, we also compared the trafficking 
of lung DC–activated OTII and CCR4/ OTII T cells in 
response to infection with H1ova. Lung, MLN, and SLN 
DC–activated Thy1.2+ OTII cells and lung DC–activated 
Thy1.2+ CCR4/ OTII cells were generated in vitro and 
adoptively transferred into separate naive Thy1.1+ recipient 
mice that were rested for 72 h and then infected with 105 
PFU of H1ova intranasally. Lungs were harvested 72 h after 
infection, and the number of CD4+Thy1.2+ T cells was de-
termined. Lung DC–activated OTII cells trafficked 3-, 2.4-, 
and 3.8-fold more efficiently into the lung in response to 
intranasal H1ova compared with MLN DC–activated OTII 
cells, SLN DC–activated OTII cells, and lung DC–activated 
CCR4/ OTII cells, respectively (Fig. 7 a). Consistent with 
the trafficking defect of lung DC–activated CCR4/ OTII 
cells, we found that the mRNA levels of the CCR4 ligands 
CCL17 and CCL22 were increased in the lung upon infec-
tion with influenza with an early peak at 4 d after infection 
(Fig. 7 b). P-values are calculated between any given day and 
Figure 6. CCR4 contributes to the lung-homing advantage of 
lung DC–activated T cells. (a) RNA expression of CCR4 (CCL17 and 
CCL22), CCR6 (CCL20), and CXCR3 ligands (CXCL9 and CXCL10) in 
lungs of naive C57BL/6 mice. n = 8 mice. (b) Immunohistochemistry 
staining with CCL17 antibody (middle and right) or isotype control 
antibody (left) in lungs of naive mice (left and middle) and mice that 
received lung DC–activated OTII cells, followed by three daily inhaled 
OVA challenges (right), demonstrating CCL17 expression by both 
epithelial (top) and endothelial cells (bottom). Staining with the 
isotype control antibody in the lungs of mice that received OTII cells 
and OVA was similar to that of naive mice (not depicted). n = 13 
samples from three independent experiments. Bars, 20 µm. (c) Lung 
HI. DCs isolated from Flt3L-expanded mice were used to activate 
OTII and CCR4/ OTII cells. CFSE-labeled, lung DC–activated 
CCR4/ OTII cells and CMTMR-labeled, MLN DC– or SLN DC–activated 
CCR4/ OTII cells were mixed 1:1 and adoptively transferred into 
recipient C57BL/6 mice without OVA challenges. CFSE-labeled, lung 
DC–activated OTII cells and CMTMR-labeled, MLN DC– or SLN DC–
activated OTII cells were also mixed 1:1 and adoptively transferred 
into another set of recipient C57BL/6 mice without OVA challenges. 
Gating on 7-AADCD4+ cells within the lymphocyte gate, HI for the 
lung at 4 h after cotransfer was calculated as [CFSE+/CMTMR+]lung/
[CFSE+/CMTMR+]input. P-values are calculated between the HIs for the 
lung after the competitive transfer of CCR4/ OTII cells versus OTII 
cells. n = 6–13 mice total from two to four independent experi-
ments. (d) Lung DCs isolated from Flt3L-expanded mice were used 
to activate Thy1.2+ OTII and CCR4/ OTII cells. Lung DC–activated 
OTII and CCR4/ OTII cells were adoptively transferred into separate Thy1.1+ recipient mice, followed by three inhaled OVA challenges. Thy1.2+ OTII cells 
in the BAL and lung of recipient mice were enumerated 24 h after the last OVA challenge. n = 9 mice per group total from three independent experi-
ments. *, P < 0.05; **, P < 0.005. Data are presented as mean (±SEM).
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T cells cleared the influenza virus by day 10 after infection, 
whereas recipients of no cells, MLN DC–activated T cells, or 
SLN DC–activated T cells still harbored the virus at this time. 
These data delineate the functional consequence of lung DC 
imprinting and have direct implications for vaccine develop-
ment against influenza, a significant global public health prob-
lem. The overall efficacy of seasonal influenza vaccination was 
only 56% in the US in 2012–2013 (Centers for Disease Con-
trol and Prevention [CDC], 2013), clearly indicating the need 
for more effective approaches to vaccinate against influenza. 
Our data suggest that inhalational delivery of a vaccine against 
influenza might lead to greater protection against the virus. In 
fact, the live attenuated influenza vaccine, which is delivered 
intranasally, has been shown to be more efficacious in children 
aged 6 mo to 7 yr compared with the trivalent inactivated vac-
cine, which is administered intramuscularly (Osterholm et al., 
2012). Furthermore, IFN-–producing, influenza-responsive 
memory T cells are detected after vaccination with the intrana-
sal live attenuated influenza vaccine but not the intramuscular 
homing on CD4+ T cells because lung DC–activated T cells had 
a homing advantage only into the lung. Lung DC–activated 
T cells did not home more efficiently into the gut compared 
with MLN DC–activated T cells in response to oral antigen, 
and they did not home more efficiently into the skin com-
pared with SLN DC–activated T cells in response to epicuta-
neous antigen.
We demonstrate that lung DC imprinting promotes lung 
immunity. Lung DC–activated T cells trafficked 3- to 2.4-fold 
more efficiently into the lung in response to pulmonary in-
fection with influenza compared with MLN and SLN DC–
activated T cells, respectively. This enhanced lung homing 
allowed lung DC–activated T cells, in turn, to provide greater 
protection against influenza compared with gut and skin 
DC–activated T cells. Recipients of lung DC–activated T cells 
lost less weight (19 vs. 25–30%) over a shorter duration (7 vs. 
8–11 d) and demonstrated greater survival (90 vs. 47–58%) 
compared with recipients of no cells or MLN or SLN DC–
activated T cells. Finally, mice that received lung DC–activated 
Figure 7. Lung DC–activated T cells protect against influenza. DCs isolated from Flt3L-expanded mice were used to activate Thy1.2+ OTII  
or CCR4/ OTII cells in vitro. DC-activated T cells were adoptively transferred into separate Thy1.1+ C57BL/6 recipient mice. 72 h after adoptive 
transfer, mice were infected intranasally with 105 PFU of a live OVA323–339 expressing PR8-H1N1 influenza virus (H1ova). Lungs were harvested  
72 h after infection for analysis. (a, left) Number of Thy1.2+ OTII cells in the lung from recipients of DC-activated T cells infected with H1ova.  
n = 5–8 mice per group in two independent experiments. P-values are calculated between recipients of lung DC-activated OTII cells versus other 
groups. (right) Lung flow cytometry from recipients of DC-activated T cells infected with H1ova, demonstrating Thy1.1+ (y axis) versus Thy1.2+  
(x axis) cells in the CD4+ gate within the lymphocyte gate. (b) RNA expression of CCL17 and CCL22 in the lungs of mice that were infected with 
H1ova. n = 6–14 mice per time point in three independent experiments. (c–e) Recipients of either no cells or lung, MLN, or SLN DC–activated OTII 
cells or lung DC–activated CCR4/ OTII cells were infected with H1ova as in a. n = 16–42 mice per group total from 4–11 independent experi-
ments for c and d. n = 5–13 mice per group total from four independent experiments for e. (c) Percentage of original weight versus days after 
infection. (d) Percentage of surviving mice versus days after infection. (e) Viral RNA copies for the polymerase gene of the PR8 influenza virus in 
the lungs at day 10 after infection. *, P < 0.05; **, P < 0.005; ***, P < 0.0005. Data for a–e are presented as mean (±SEM).
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Our study illuminates the role of DCs in CCR4 expres-
sion and the role of CCR4 in tissue-selective T cell homing. 
Although nearly all CLA+CD4+ T cells in the skin and the 
blood are CCR4+ (Campbell et al., 1999; Kunkel et al., 2002; 
Soler et al., 2003; Clark et al., 2006), skin DCs have not been 
shown to imprint CCR4 expression. Instead, skin DCs im-
print CCR10, which is expressed only by a small subset of 
skin homing T cells (Sigmundsdottir et al., 2007). Recently, 
epidermal keratinocyte have been shown to imprint CCR8 
(McCully et al., 2012) and not CCR4. Furthermore, although 
nearly all memory CLA+ T cells in the blood are CCR4+, not 
all peripheral blood CCR4+ T cells are CLA+ (Soler et al., 
2003). This observation indicates that despite its prominent 
role in T cell trafficking into the skin (Reiss et al., 2001; 
Campbell et al., 2007; Oyoshi et al., 2011), CCR4 is not 
an exclusive skin-homing molecule. In addition to dermal 
post capillary venules (Campbell et al., 1999), lung epithelial 
(Kawasaki et al., 2001) and endothelial cells express CCL17, a 
CCR4 ligand. CCR4 contributes to effector and regulatory 
T cell trafficking into the lung during inflammation (Lloyd 
et al., 2000; Mikhak et al., 2009; Afshar et al., 2013), and 
CCR4 deficiency in regulatory T cells results in severe in-
flammatory disease not only in the skin but also in the lung 
(Sather et al., 2007). Our data demonstrate that lung DCs 
imprint the expression of CCR4 on T cells and that CCR4 
expression by lung DC–activated T cells promotes T cell traf-
ficking into the lung at homeostasis as well as in response to 
inhaled antigens and the pulmonary pathogen influenza.
We saw no statistically significant difference in the expres-
sion of CCR4, 47, and E-selectin ligand between in vitro–
generated lung DC– and SLN DC–activated T cells after 
5 d in culture. The many similarities in the expression of 
trafficking molecules between lung and SLN DC–activated 
T cells and the expression of CCR4 ligands in both the lung 
(Kawasaki et al., 2001) and the skin (Campbell et al., 1999; 
Chong et al., 2004) suggest that SLN DC–activated T cells 
could potentially home to the lung and lung DC–activated 
T cells could potentially home to the skin. Consistent with 
this lung–skin connection, small pox vaccination via skin 
scarification has been shown to generate lung-resident mem-
ory T cells that provide partial protection against fatal small 
pox pulmonary infection (Liu et al., 2010). However, we ob-
served that despite their in vitro similarities in the expression 
of trafficking molecules, lung and SLN DC–activated T cells 
trafficked differentially in vivo. The smallest differential was 
observed within 4 h of adoptive transfer in the absence of an-
tigen, when lung DC–activated T cells demonstrated a 1.5-fold 
homing advantage into the lung and a 1.4-fold homing ad-
vantage into PPs compared with SLN DC–activated T cells. 
The in vivo trafficking differential between lung and SLN 
DC–activated T cells widened with antigen exposure over time. 
Lung DC–activated T cells trafficked 2.3- to 6.6-fold more 
efficiently into the lung compared with SLN DC–activated 
T cells in response to inhaled antigen challenges or pulmo-
nary infection with influenza. Furthermore, SLN DC–activated 
T cells trafficked 2.5-fold more efficiently into the ear skin 
trivalent inactivated vaccine in children 6–35 mo old (Hoft 
et al., 2011). These clinical differences could stem from the 
fact that one vaccine is live attenuated whereas the other is 
killed and inactivated, but based on our data, it could also re-
sult from differences in the route of exposure.
We show that lung DCs imprint T cell lung homing in 
part through CCR4. First, lung DCs imprint higher levels of 
CCR4 on CD4+ T cells compared with gut DCs. This ob-
served differential is consistent with the published literature 
(Dudda et al., 2004; Mora et al., 2005), which demonstrates 
that retinoic acid down-regulates CCR4 mRNA expression 
(Iwata et al., 2004). Second, the ligand for CCR4, CCL17, is 
expressed by epithelial cells (Kawasaki et al., 2001) and on the 
luminal aspect of endothelial cells both in the lungs of naive 
mice and mice that were given lung DC–activated T cells and 
inhaled antigen challenges. Third, the lung-homing advantage 
of lung DC–activated T cells at homeostasis is proportional to 
their differential level of CCR4 expression with a 3-fold lung 
homing advantage compared with MLN DC–activated T cells, 
which express the lowest levels of CCR4, and a 1.6-fold lung-
homing advantage compared with SLN DC–activated T cells, 
which express intermediate levels of CCR4. We show that 
CCR4 deficiency decreased the lung-homing advantage of 
lung DC–activated T cells over MLN DC–activated T cells at 
homeostasis. Fourth, CCR4 deficiency also compromised the 
trafficking of lung DC–activated T cells into the BAL and 
lung in response to inhaled antigen (4.6- and 1.9-fold, respec-
tively). Fifth, and perhaps most importantly, CCR4-deficient, 
lung DC–activated T cells showed a 3.8-fold decrease in traf-
ficking into the lung in response to pulmonary infection with 
influenza and subsequently failed to protect against influenza 
as effectively as CCR4-sufficient, lung DC–activated T cells. 
There was a rise in the expression of CCR4 ligands in the 
lungs of infected mice, which peaked at 4 d after infection and 
correlated with the trafficking defect of lung DC–activated, 
CCR4-deficient T cells. The detrimental impact of this early 
trafficking defect is in agreement with a study demonstrating 
that survival is compromised the most when antigen-specific 
T cells are eliminated early in the course of infection with 
influenza (Hamada et al., 2013). The deleterious impact of 
CCR4 deficiency in the ability of lung DC–activated T cells 
to protect against influenza could perhaps be explained by the 
observation that influenza-specific CD4+ T cells contribute 
to viral clearance by inducing the early release of a large num-
ber of innate inflammatory cytokines and chemokines within 
40 h of infection (Strutt et al., 2010). Our observation with 
regard to influenza is consistent with the literature that sup-
ports a role for CCR4 in T cell immune responses to other 
respiratory pathogens (Freeman et al., 2006; Hartl et al., 2006; 
Stolberg et al., 2011; Shankar et al., 2012). We observed that 
recipients of CCR4-deficient, lung DC–activated T cells lost 
more weight (23 vs. 19%) for longer (8 vs. 7 d), had lower rate 
of survival (70 vs. 90%), and continued to harbor the influ-
enza virus at day 10 after infection. Therefore, our data collec-
tively demonstrate that lung DCs imprint T cell lung homing 
in part through CCR4.
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not sufficient to endow TLN DCs with lung-imprinting abil-
ities. The number of lung-imprinting DCs that migrate from 
the lung to the TLN in response to inhaled antigen must 
make up a small fraction of all lung-imprinting DCs in the 
lung as the ability of lung DCs to imprint lung homing did 
not change with inhaled antigen exposure. Our observations 
collectively suggest that T cells activated in the TLN, per-
haps in response to circulating antigens, are not imprinted 
with lung homing, a phenomenon which might prevent ex-
cessive T cell–mediated immune responses in the lung. T cell 
lung imprinting in the TLN requires inhaled antigen expo-
sure and mobilization of lung-imprinting DCs from the lung 
to the TLN.
Our findings advance our understanding of tissue-selective 
T cell imprinting at epithelial surfaces. We show that lung 
DCs imprint T cell lung homing and, in doing so, promote 
lung immunity against pulmonary infection with influenza in 
part via CCR4. Our findings suggest that inhalational deliv-
ery of a vaccine against influenza might improve protection 
against this important global human pathogen. Our study opens 
up a large area of research to fully define the mechanisms 
through which DC lung imprinting is accomplished. Future 
studies will define the role of lung DC subsets and lung 
microenvironmental factors and the nature of DC–T cell in-
teractions in T cell lung imprinting.
MATERIALS AND METHODS
Mice. All mice were in the C57BL/6 background. Wild-type Thy1.2+ male 
C57BL/6 mice were purchased from the National Cancer Institute, Taconic, 
or the Jackson Laboratory and used as DC donors or recipients in adoptive 
transfer experiments. Thy1.1+ OTII mice, which are transgenic for the TCR 
recognizing pOVA323–339, were a gift from P. Shrikant (Roswell Park Cancer 
Institute, Buffalo, NY), bred in our laboratory, and used as CD4+ T cell do-
nors. In some experiments, Thy1.2+ OTII mice were purchased from the 
Jackson Laboratory and were used as CD4+ T cell donors, and Thy1.1+ mice, 
also from the Jackson Laboratory, were used as recipients. Thy1.2+CCR4/ 
OTII mice, also used as CD4+ T cell donors, were backcrossed at least 10 
generations to C57BL/6, generated as previously described, and bred in our 
laboratory (Chvatchko et al., 2000; Mikhak et al., 2009). In experiments 
comparing OTII and CCR4/ OTII cells, Thy1.2+ OTII cells that had 
been purchased from the Jackson Laboratory and bred in our animal facility 
were used. Thy1.2+ OTI mice, which are transgenic for the TCR recognizing 
pOVA257–264, were purchased from the Jackson Laboratory. As a control for 
mice housed solely in our animal facility, we repeated our experiments using 
mice housed in different animal facilities. Similar results were obtained when 
we used Thy1.1+ OTII mice bred in our animal facility or Thy1.2+ OTII 
mice bred at the Jackson Laboratory as T cell donors and whether we used 
naive Thy1.2+ or Thy1.1+ C57BL/6 mice from the National Cancer Insti-
tute, Taconic Farms, or Jackson Laboratory as recipients. Mice were age and 
gender matched and used at 6–8 wk of age. Mice were housed under specific 
pathogen–free conditions. All experiments were performed according to 
protocols approved by the Massachusetts General Hospital Subcommittee on 
Research Animal Care.
In vivo expansion of DCs, DC isolation, and DC–T cell cultures. A 
minimum of 1 million DCs from each site was needed for DC–T cell cul-
tures to generate enough T cells to inject three to four mice per group per 
experiment. To expand DC numbers, naive C57BL/6 mice were injected in 
the interscapular area with B16 Flt3L-secreting melanoma cells, a gift from 
G. Dranoff (Dana-Farber Cancer Institute, Boston, MA; Mach et al., 2000). 
On days 12–14, PBS-flushed lungs, TLN, spleen, SLN, MLN, ears (for DC 
compared with lung DC–activated T cells in response to tape 
stripping and epicutaneous antigen challenges. These data 
collectively suggest that the expression of trafficking mole-
cules on lung and SLN DC–activated T cells might diverge in 
vivo upon antigen exposure.
We show that lung DC imprinting leads to both tissue-
selective and systemic T cell distribution. Lung DCs endow 
T cells with a lung-homing advantage and also license them 
for entry into other epithelial organs at homeostasis. Lung 
DC–activated T cells home into PPs as well as MLN DC– 
activated T cells and home into SLNs better than MLN 
DC–activated T cells. Furthermore, lung DC–activated T cells 
home into SLNs as well as SLN DC–activated T cells and 
home into PPs better than SLN DC–activated T cells. There-
fore, lung DC–activated T cells are more liberal in their systemic 
distribution compared with SLN and MLN DC–activated 
T cells. The wide distribution of lung DC–activated T cells 
could be explained by their expression of 47 and E-selectin 
ligand. Lung DC imprinting appears compatible with the 
acquisition of systemic T cell immunity. In systemic T cell 
immunity, exposure to a pathogen in one tissue leads to dis-
tribution of pathogen-experienced T cells both into the orig-
inal site and into other tissues, where some pathogen-specific 
T cells persist long-term (Masopust et al., 2001, 2004), and 
provide a ready line of T cell defense for swift eradication of 
invading pathogens through immediate cytokine release and 
cytotoxic activities (Masopust et al., 2001; Teijaro et al., 2011; 
Jiang et al., 2012). Our findings imply that exposure to in-
haled antigen results in the generation of antigen-experienced 
T cells that not only populate the lung but also could con-
tribute to the pool of tissue-resident T cells in other epithelial 
organs at distant sites. Indeed, influenza-specific memory T cells 
are detected in small intestinal epithelium after intranasal in-
fluenza infection (Masopust et al., 2010). Furthermore, anti-
gen-specific T cells activated in lung-draining LNs are found 
in nondraining SLNs and MLNs within 5 d after intranasal 
exposure (Ciabattini et al., 2011). Collectively, our results 
imply that inhalational delivery of vaccines might provide bet-
ter lung immunity while also establishing efficient T cell pro-
tection at other epithelial organs.
Our data suggest that lung-imprinting DCs reside in the 
lung and not in lung-draining LNs at homeostasis. One pos-
sible explanation is that lung-imprinting DCs are not present 
in the TLN in sufficient numbers at baseline to imprint T cell 
lung homing. Another possibility is that a factor in the TLN 
inhibits the function of lung-imprinting DCs at homeostasis 
(Lee et al., 2009). However, we observed that TLN DCs ac-
quired the ability to imprint T cell lung homing 24 h, but 
not 30 min, after inhaled antigen exposure, when there is suf-
ficient time for DC migration from the lung to the TLN 
(Vermaelen et al., 2001). This suggests that lung-imprinting 
DCs are migratory DCs that travel from the lung to the TLN 
upon exposure to inhaled antigen and take with them the 
ability to imprint lung homing to the TLN. It also suggests 
that passive drainage of antigen or soluble factors from the lung 
to the TLN, which occurs within minutes (Gretz et al., 2000), is 
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In vivo competitive adoptive transfer model. On day 6, lung DC– 
activated T cells were labeled with 1 mM CFSE (Molecular Probes), whereas 
MLN and SLN DC–activated T cells were labeled separately with 9 mM 
CMTMR (Molecular Probes) for 15 min at 37°C, spun over fetal calf serum, 
incubated in RPMI at 37°C for 15 min, and washed in PBS twice. CFSE- 
labeled, lung DC–activated T cells were mixed with CMTMR-labeled, MLN 
or SLN DC–activated T cells at 1:1 ratio at 20 million cells per ml and in-
jected via the tail vein into naive recipient mice at 0.5 ml per mouse. The 
ratio of input cells was determined using flow cytometry before adoptive 
transfer. 4 h after adoptive transfer, the lung, spleen, PPs, and SLNs (inguinal) 
were isolated. Single cell suspensions from each site were prepared and stained 
with 7-AAD and allophycocyanin (APC)-labeled, anti–mouse CD4 anti-
body. The percentage of CFSE-labeled (lung DC activated) and CMTMR-
labeled (MLN or SLN DC activated) cells in the 7-AADCD4+ gate within 
the lymphocyte gate was determined in each tissue by flow cytometry. 
HI was calculated as [percentage of CFSE+ cells/percentage of CMTMR+ 
cells]tissue/[percentage of CFSE+ cells/percentage of CMTMR+ cells]input. In 
control experiments, dyes were switched with similar results.
Recovery of mouse tissue leukocytes. BAL was performed 24 h after the 
final aerosol challenge with six 0.5-ml aliquots of PBS with 0.6 mM EDTA. 
PBS-flushed lungs were minced and digested for 30 min as above. Single cell 
suspensions were made from lungs, spleen, PPs, and SLNs after passage 
through a 70-µm cell strainer (Thermo Fisher Scientific). Red blood cells 
were lysed as above when needed. To recover T cells from the mouse ear, ears 
were minced for 1 min, digested in 8 ml HBSS containing 10% fetal calf 
serum and Collagenase IV (Sigma-Aldrich) at 154 U/ml at 37°C for 45 min, 
and passed through a 70-µm cell strainer. Isolation of lymphocytes from LP 
was performed as previously described (Shang et al., 2009). Live cells were 
counted with a hemocytometer. To determine the number of adoptively 
transferred cells in each compartment, the total number of cells was multi-
plied by the percentage of CD4+Thy1.1+ cells when Thy1.1+ OTII cells 
were transferred into Thy1.2+ recipients or by the percentage of CD4+Thy1.2+ 
cells when Thy1.2+ OTII cells were transferred into Thy1.1+ recipients.
Infection with influenza. 3 d after adoptive transfer of DC-activated 
T cells, recipient mice were anesthetized with i.p. injection of 80–100 mg/kg 
ketamine HCl and 12 mg/kg xylazine. Mice were infected with a live 
OVA323–339-expressing PR8-H1N1 influenza virus (Thomas et al., 2006) at 
105 PFU in 50 µl PBS per mouse intranasally. Some mice were euthanized on 
day 3 after infection, and the lungs were harvested and the number of adop-
tively transferred T cells was determined as described above. Other mice were 
monitored for weight loss and survival daily for 14–18 d.
Flow cytometry. Flow cytometry was performed on a FACScan (BD) cyto-
fluorometer, and results were analyzed with FlowJo software(Tree Star). Cells 
were incubated with anti-FcIII/FcII receptor (BioLegend) for 10 min 
and then stained with fluorescent-labeled monoclonal antibodies from 
R&D Systems (CCR1-3, CCR9-10, CXCR2, and CXCR5-6), eBioscience 
(CCR5, CXCR4, CD29, CD49e, CD103, CD43, and CD41), BioLegend 
(CD4, CD11c, CD44, Thy1.1, Thy1.2, IL-4, IL-17a, IFN-, CD103, CCR4, 
CCR6, CCR7, CXCR3, CD61, b7, CD104, CD49a, CD49b, CD49f, CD51, 
CD11b, CD43, MHC II, CD86, CD2, and F4/80), and BD (47, CD3, 
CD19, CD69, CD25, CD62L, CD49a, VLA-4, and LFA-1). Recombinant 
mouse E-selectin/CD62E Fc chimera (R&D Systems) and APC-conjugated 
affinity pure F(ab)2 fragment goat anti–human IgG Fc fragment specific 
(Jackson ImmunoResearch Laboratories, Inc.) were used for E-selectin li-
gand staining. For proliferation and apoptosis, APC BrdU flow kit (BD) and 
7-AAD Viability Staining Solution (BioLegend) were used, respectively. 
Staining for CCR8 was not performed because of a lack of commercially 
available validated antibodies.
In vitro–generated, DC-activated T cells were rested (by replacing the 
media in each well with fresh media) for 4 h at 37°C before staining for traf-
ficking molecules. All staining was performed for 20 min at 4°C except for 
CCR7 staining, which was performed for 30 min at 37°C. Freshly prepared, 
azide-free FACS buffer was used.
isolation from the skin), jejunum, and ileum (for DC isolation from LP) were 
isolated from the same donor pool. Minced lungs, spleens, and LNs were di-
gested in RPMI medium containing 0.52 Wunsch U/ml of Liberase and 
60 U/ml DNase I (both from Roche) at 37°C. Length of digestion was opti-
mized for each tissue to maximize yield and minimize cell death. Red blood 
cell lysis buffer (Sigma-Aldrich) was used for 1–3 min when needed. LP and 
skin DCs were isolated as described previously (Jakubzick et al., 2008; Helft 
and Merad, 2010). CD11c+ cells were isolated using anti-CD11c microbeads 
(Miltenyi Biotec). In some experiments, Flt3L-expanded mice were given an 
intranasal dose of OVA (50 µl at 2 mg/ml; Sigma-Aldrich) with or without 
8 µg of intranasal CCR4 or CCR7 blocking antibody (both from Capralog-
ics; Fainaru et al., 2005), and CD11c+ cells were isolated from the lung and 
TLN either 30 min or 24 h later. In control experiments, Flt3L-expanded 
mice were given an intranasal dose of FITC-labeled OVA (50 µl at 2 mg/ml; 
Molecular Probes) with or without intranasal CCR4 or CCR7 blocking 
antibody as above, and TLNs were harvested 48 h later. In other experiments, 
adequate numbers of lung, spleen, and SLN CD11c+ cells were obtained 
by using up to 20 naive unexpanded C57BL/6 mice and pooling each tissue. 
In those experiments, single cell preparations of unexpanded tissues were 
rested overnight before isolation of CD11c+ cells. CD4+ T cells were iso-
lated from the pooled LNs and spleen of OTII mice (Thy1.1+ or Thy1.2+ 
OTII or Thy1.2+CCR4/ OTII depending on the experiment) using 
Dynabeads (Invitrogen). DC–T cell cultures were established at a 1:1 ratio 
using pOVA323–339 (final concentration = 2 µg/ml or 1.1 µM; Peptides In-
ternational), without exogenous cytokines in complete culture medium 
(RPMI supplemented with 10% heat-inactivated fetal calf serum, 10 mM 
Hepes, 2 mM l-glutamine, 50 µM -mercaptoethanol, 100 U/ml penicil-
lin, 100 µg/ml streptomycin, and 0.1 mM nonessential amino acids) at 
1 million cells per ml in flat bottom 96-well plates. Cells were fed with fresh 
media (not containing any cytokines) daily starting on day 2 of culture and 
split 1:2 starting on day 3. On day 5 of culture, surface staining was per-
formed for trafficking molecules. On day 6 of culture, surface staining for 
activation markers and intracellular staining for cytokines were performed 
as described previously (Mikhak et al., 2006) to ensure equal differentiation 
and activation among groups.
CD8+ T cells were isolated from the pooled LNs and spleen of OTI 
mice via negative selection using the mouse CD8a+ T cell isolation kit II 
from Miltenyi Biotec. DCs were pulsed with pOVA257–264 (final concentra-
tion = 9.6 µg/ml or 10 µM; Peptides International) at 10 million cells per ml 
for 1 h and washed twice. DC–T cell cultures were established at a 1:2 ratio 
without exogenous cytokines in complete culture media at 1.5 million cells 
per ml in flat bottom 96-well plates. Cells were fed and split as above.
In vivo separate adoptive transfer model. On day 6 or 7, DC-activated 
T cells were adoptively transferred via the tail vein, at 2 × 106 cells in 0.5 ml 
per mouse, into separate naive recipient mice. Thy1.1+ OTII cells were trans-
ferred into Thy1.2+ recipient mice. Thy1.2+ OTII or OTI cells were trans-
ferred into Thy1.1+ recipients. 24–72 h after adoptive transfer, mice were 
given three daily aerosolized 5% OVA (Sigma-Aldrich) challenges, for 20 min 
each day, using a nebulizer (Pulmo Aide). In some experiments, mice were 
evaluated 72 h after adoptive transfer without any OVA challenges. In other 
experiments, mice were given one oral or one i.p. challenge with 100 µl 
of 5% OVA. For in vivo proliferation experiments, mice were injected with 
0.2 ml BrdU (Sigma-Aldrich) i.p. at 10 mg/ml before the third OVA chal-
lenge. 2 h after the third challenge, TLNs were isolated and the percentage of 
BrdU+CD4+Thy1.1+ cells in the lymphocyte gate was determined. In other 
experiments, in vitro–generated CD4+ T cells were resuspended at 4 × 105 
cells/ml on day 5, treated with PTX (100 ng/ml; Sigma-Aldrich) or vehicle 
(distilled H2O) for 24 h, and then washed twice with PBS before their adop-
tive transfer. To assess T cell trafficking into the ear skin, DC-activated Thy1.2+ 
OTII cells were adoptively transferred via the tail vein, at 12 × 106 cells in 
0.5 ml per mouse, into separate Thy1.1+ recipient mice. 24 h after adoptive 
transfer, the outer surface of each ear was tape stripped 12 times using Scotch 
Matte Finish Magic Tape (3M), and 25 µl of 5% OVA was applied epicutane-
ously. The procedure was repeated daily for 3 d.
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